nitroxy-butyl-acetylsalicylic acid

structure given in first source
Also Known As:
Networked: 53 relevant articles (2 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Rigas, Basil: 20 articles (06/2011 - 10/2003)
2. Kashfi, Khosrow: 15 articles (01/2015 - 10/2003)
3. Williams, Jennie L: 10 articles (07/2012 - 11/2003)
4. Ouyang, Nengtai: 7 articles (06/2011 - 01/2004)
5. Gao, Jianjun: 7 articles (04/2006 - 11/2003)
6. Nath, Niharika: 6 articles (01/2015 - 10/2003)
7. Kopelovich, Levy: 5 articles (06/2011 - 11/2003)
8. Chen, Jie: 5 articles (10/2005 - 10/2003)
9. Chattopadhyay, Mitali: 4 articles (01/2015 - 11/2009)
10. Liu, Xiaoping: 4 articles (02/2008 - 10/2005)

Related Diseases

1. Neoplasms (Cancer)
2. Colonic Neoplasms (Colon Cancer)
3. B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
4. Breast Neoplasms (Breast Cancer)
5. Ulcer
07/01/2001 - "The area of gastric ulcer was determined by planimetry, the gastric blood flow (GBF) at ulcer margin was measured by H2 gas clearance method and mucosal release of ROS was quantified by measuring the chemiluminescence before and after the treatment with ASA or NO-ASA alone and ASA combined with vitamin C. "
12/01/2004 - "Previous studies have demonstrated that the gastric mucosa of diabetic rats is highly vulnerable to acute injury but the influence of nonsteroidal anti-inflammatory drugs (NSAID) and their new nitric oxide (NO) releasing derivatives of aspirin (NO-ASA) on the ulcer healing under diabetic conditions has been little studied. "
12/01/2004 - "In contrast to ASA, the treatment with NO-ASA failed to influence both, the ulcer healing and GBF at ulcer margin and significantly attenuated the plasma levels of IL-1beta, TNF-alpha and IL-10 as compared to those recorded in ASA- or rofecoxib-treated animals. "
07/01/2001 - "In this study the effect of NO-releasing aspirin (NO-ASA) and was compared with that of native aspirin applied with or without vitamin C on the healing of acetic acid ulcers. "
12/01/2004 - "We conclude that: 1) ulcer healing is dramatically impaired in experimental diabetes and this effect involves the fall in the gastric microcirculation at the ulcer margin and increased release of proinflammatory cytokines; 2) classic NSAID such as ASA and selective COX-2 inhibitors such as rofecoxib, prolong ulcer healing under diabetic conditions probably due to suppression of endogenous PG and the fall in the GBF at the ulcer margin suggesting that both COX isoforms, namely, COX-1 and COX-2, are important sources of PG during ulcer healing in diabetes; and 3) NO-ASA counteracts the impairment of ulcer healing in diabetic rats induced by ASA, mainly due to the release of NO that compensates for PG deficiency resulting in enhancement in the GBF at ulcer margin and suppression of cytokine release in the ulcer area."

Related Drugs and Biologics

1. N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester
2. Aspirin (Acetylsalicylic Acid)
3. Nitric Oxide (Nitrogen Monoxide)
4. Acetic Acid (Vinegar)
5. nitrosobis(2-oxopropyl)amine (NBOP)
6. Caspase 3 (Caspase-3)
7. Ascorbic Acid (Vitamin C)
8. N-methylsuccinimide
9. beta Catenin
10. nitroaspirin

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Chemoprevention
3. Transplants (Transplant)
4. Stents
5. Injections